Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on uniQure on July 29 and set a price target of $48.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Schwartz has given his Buy rating due to a combination of factors including the promising potential of uniQure’s lead program, AMT-130, which targets Huntington’s disease. This program is positioned to be the first disease-modifying therapy for a condition with a significant unmet need. The company is making strong progress in several critical areas such as clinical development, regulatory alignment, and preparations for commercial launch, which are expected to drive significant developments in the latter half of 2025.
Additionally, uniQure has achieved regulatory alignment with the FDA on their statistical analysis plan and CMC requirements, which is a positive indicator for the company’s future prospects. The focus on a primary efficacy analysis based on the 3-year change in the composite Unified Huntington’s Disease Rating Scale further supports the potential for success. The absence of a specified minimal threshold for clinical benefit from the FDA adds an element of flexibility, which, combined with the company’s strategic approach, enhances the potential for positive outcomes and stock performance.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $70.00 price target.
QURE’s price has also changed moderately for the past six months – from $15.240 to $13.680, which is a -10.24% drop .